Paxil CR Labeling Adds Birth Defects Warning Based On U.S., Swedish Data
FDA deemed a birth defects warning for GlaxoSmithKline's Paxil CR to be warranted after data from a Swedish birth registry supported an analysis of a U.S. managed care claims database, the agency said
You may also be interested in...
GlaxoSmithKline is conducting additional epidemiologic studies to better understand preliminary data suggesting a potential link between paroxetine use and birth defects, the company said in a "Dear Doctor" letter on revised labeling for Paxil CR and Paxil
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials